Ghent University Academic Bibliography

Your filters: cql: author="Barbezange, Cyril" or (type any "bookEditor issueEditor" and editor="Barbezange, Cyril")

Add to list
- Journal Article
- A1
- open access
Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting : a randomized placebo-controlled phase II trial

Els Tobback (UGent) , Sophie Degroote (UGent) , Sabine Buysse, Liesbeth Delesie (UGent) , Lucas Van Dooren, Sophie Vanherrewege (UGent) , Cyril Barbezange, Veronik Hutse, Marta Romano, Isabelle Thomas, et al.

(2022) INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 122. p.628-635
Add to list
- Journal Article
- A1
- open access
Functional analysis of human and feline coronavirus cross-reactive antibodies directed against the SARS-CoV-2 fusion peptide

Nathalie Vanderheijden (UGent) , Annelies Stevaert, Jiexiong Xie (UGent) , Xiaolei Ren (UGent) , Cyril Barbezange, Sam Noppen, Isabelle Desombere, Bruno Verhasselt (UGent) , Peter Geldhof (UGent) , Nick Vereecke (UGent) , et al.

(2022) FRONTIERS IN IMMUNOLOGY. 12.
Add to list
- Journal Article
- A1
- open access
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients : DAWn-plasma

Timothy Devos, Quentin Van Thillo, Veerle Compernolle (UGent) , Tomé Najdovski, Marta Romano, Nicolas Dauby, Laurent Jadot, Mathias Leys, Evelyne Maillart, Sarah Loof, et al.

(2022) EUROPEAN RESPIRATORY JOURNAL. 59(2).
Add to list
- Journal Article
- A1
- open access
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 : the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Timothy Devos, Tatjana Geukens, Alexander Schauwvlieghe (UGent) , Kevin K. Arien, Cyril Barbezange, Myriam Cleeren, Veerle Compernolle, Nicolas Dauby, Daniel Desmecht, David Grimaldi, et al.

(2020) TRIALS. 21(1).

Academic Bibliography

Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting : a randomized placebo-controlled phase II trial

Functional analysis of human and feline coronavirus cross-reactive antibodies directed against the SARS-CoV-2 fusion peptide

Early high antibody titre convalescent plasma for hospitalised COVID-19 patients : DAWn-plasma

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 : the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Contents

Support

Contact